Pionyr Immunotherapeutics
South San Francisco
About Pionyr Immunotherapeutics
Pionyr Immunotherapeutics is developing cancer immunotherapies that target the tumor microenvironment to enhance the body’s antitumor immunity. The company is exploiting novel target discovery and antibody generation platform technologies to create the next generation of immuno-oncology therapeutics. The company’s approach, Myeloid Tuning™, is designed to enhance the immune system’s anti-tumor response by altering the cellular infiltrate of the tumor microenvironment with high specificity.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Estimated revenue: $1K – $10K
- Total funding: $352.0M
- Funding stage: M&A
- Last round: Corporate Round (Jun 2020)
- Website: pionyrtx.com
- Phone: (415)226-7503
Industries & Categories
Biotechnology, Medical, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/pionyr-immunotherapeutics-30531 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.